Switching from Tirzepatide to Retatrutide: A Microdosing Perspective
Switching between GLP-1s on a microdose schedule is gentler than the weekly equivalent. Smaller daily doses give your body time to adapt at each step, and the lower peak concentrations reduce the side-effect spike that often hits during transitions. Microdose-to-microdose conversions can usually be done overnight; weekly-to-microdose transitions need a 1-2 week wash-down period. The conversion ratios below apply, with adjustments noted for split protocols.
Important Disclaimer
This article is for research purposes only. Any medication changes should be discussed with your healthcare provider. The information provided is based on available research data and should not be used for medical decision-making.
Overview
Switching from Tirzepatide (Mounjaro/Zepbound) to Retatrutide involves transitioning from a dual agonist (GLP-1/GIP) to a triple agonist (GLP-1/GIP/glucagon). This guide covers the benefits, risks, and considerations for making this switch.
Potential Benefits
- Additional glucagon receptor activity
- Enhanced metabolic effects
- Potential for greater weight loss
- Once-weekly dosing
- Maintained GIP activity
Potential Drawbacks
- Limited clinical experience
- Need to restart titration
- Different side effect profile
- Research phase medication
- May require dose adjustment
Dose Conversion
When switching from Tirzepatide to Retatrutide, it's important to follow proper dose conversion guidelines. Use our calculator to determine the appropriate starting dose:
GLP-1 Dose Conversion CalculatorSide Effects During Transition
When switching medications, you may experience:
- Gastrointestinal symptoms
- Changes in appetite
- Blood sugar fluctuations
- Energy level changes
- Potential metabolic changes